Day: February 28, 2024

SHANGHAI, China, Feb. 28, 2024 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced unaudited financial results for the quarter ended December 31, 2023. “ECARX closed out 2023 on a high note, delivering a 31% year-over-year increase in revenues and significantly narrowing our net loss for the full year,” said ECARX Chairman and CEO Ziyu Shen. “Our innovative digital cockpit solutions are gaining considerable traction in the market as we bring our sophisticated in-car experience to new EV models with truly international reach and build stronger brand awareness among global automotive OEMs. This was reflected in the launch of the Polestar 4 and Volvo EX30 during the quarter which showcased our customized OS and Cloudpeak software stack. We also added one...

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 44th Annual Health Care Conference, which takes place in Boston on March 4-6. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at 9:50 am ET during the conference and host investor meetings on March 5. A webcast of the presentation will be available here beginning at 9:50 am ET on Tuesday, March 5 and will be posted on the Investors section of the Company’s website. About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:TD Cowen 44th Annual Health Care Conference (Boston, Massachusetts)Tuesday, March 5, 2024, at 10:30 a.m. ET, panelLeerink Partners Global Biopharma Conference (Miami, Florida)Tuesday, March 12, 2024, at 10:40 a.m. ET, corporate presentationBarclays 26th Annual Global Healthcare Conference (Miami, Florida)Wednesday, March 13, 2024, at 2:05 p.m. ET, fireside chatStifel 2024 CNS Days (Virtual)Tuesday, March 19, 2024, at 11:30 a.m. ET, fireside chatA webcast of each conference presentation will be available on the “Events & Presentations” page within the...

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024. Barclays 26th Annual Global Healthcare Conference Fireside ChatDate:  Thursday, March 14, 2024Time: 7:30 – 7:55 AM ETThe PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Barclays representative. About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered,...

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) is pleased to announce that the Company will ring the opening bell at the Toronto Stock Exchange (“TSX”) on Friday, March 1, 2024, at 9:30 AM ET to commemorate its recent listing under the symbol “PUR”. A live webcast of the ceremony is expected to be available beginning shortly before 9:30 AM ET on BNN Bloomberg and on YouTube at https://youtube.com/live/2MzWz_Id0Zw?feature=share. Tim Rotolo, CEO and Director, commented, “Being listed on Canada’s most senior stock exchange reflects our commitment to creating value for our shareholders and we greatly appreciate the opportunity to ring the opening bell this week. With uranium fundamentals remaining strong, we are encouraged by the early response...

Germany’s De-Scheduling of Cannabis Opens Path to New Opportunities for Tilray in Potential $3bn Medical Market European Union Medical Cannabis Market Now Projected to Become $45bn NEW YORK and NEUMÜNSTER, Germany, Feb. 28, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today provides an update on Germany’s milestone cannabis legalization and what it means for the future of cannabis in Europe and for Tilray. As a global leader in the legalized medical and adult-use cannabis markets and a market leader in medical cannabis across Europe, with a leading market share in Germany, Tilray is bullish on the positive paradigm shift that the new German drug policy creates for the future of cannabis in Europe. Irwin D. Simon,...

TULSA, Okla., Feb. 28, 2024 (GLOBE NEWSWIRE) — Matrix Service Company (Nasdaq: MTRX) announced today that President and Chief Executive Officer John R. Hewitt, Vice President and Chief Financial Officer Kevin Cavanah, and Senior Director of Investor Relations Kellie Smythe, will be attending the Sidoti Small-Cap Virtual Conference on March 13 and 14, 2024. The company will present at 12:15 p.m. eastern standard time on March 14. One-on-one meetings with management are available during the conference with prior notice and may be scheduled through the conference or by contacting Matrix Service Company at ir@matrixservicecompany.com. About Matrix Service Company Matrix Service Company (Nasdaq: MTRX), through its subsidiaries, is a leading North American industrial engineering, construction, and maintenance contractor headquartered...

Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidance, prior to the open of the U.S. financial markets on Wednesday, March 6, 2024. Kamada management will host an investment community conference call on Wednesday, March 6, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products (“1stDibs” or the “Company”), today reported financial results for its fourth quarter and year ended December 31, 2023. Fourth Quarter 2023 Financial HighlightsNet revenue was $20.9 million, a decrease of 9% year-over-year. Gross profit was $15.0 million, a decrease of 8% year-over-year. Gross margin was 71.5%, compared to 70.5% in the fourth quarter 2022. GAAP net loss was $2.9 million compared to a net loss of $6.9 million in the fourth quarter 2022. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $(1.7) million and (8.1)%, respectively, compared to $(4.5) million and (19.5)%, respectively, in the fourth quarter 2022. Cash, cash equivalents and short-term investments...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen’s 44th Annual Health Care Conference, which is taking place on March 4–6, 2024, at the Boston Marriott Copley Place in Boston, MA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Leukemia panel date and time: Monday, March 4, 12:50 p.m. ETFoghorn Presenter: Alfonso Quintas-Cardama, Chief Medical Officer Please find a link to the panel here.Management will also participate in one-on-one meetings...